Comparison of a Second-Generation Combination Chemotherapeutic Regimen (m-BACOD) with a Standard Regimen (CHOP) for Advanced Diffuse Non-Hodgkin's Lymphoma
Leo I. Gordon(Northwestern University), Michael J. O’Connell(Miami University), Gene Resnick(NewYork–Presbyterian Hospital), Joseph P. Colgan(Mayo Clinic), Maurice Barcos(Roswell Park Comprehensive Cancer Center), Risa B. Mann(Boston University), Richard S. Neiman(University Medical Center), Arlan J. Gottlieb(Regional Cancer Center), Janet Andersen(Harvard University), John H. Glick(University of Pennsylvania), David Harrington
Cited by 326
Related Papers
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
|Journal of Clinical Oncology|2002|1.2k
Ensembl 2012
|Nucleic Acids Research|2011|839
The Design and Analysis of Sequential Clinical Trials.
|Journal of the American Statistical Association|1985|638